Evidence map›Paper›PMID 36243044›Full record

ArticleThe American journal of pathology2022

Integrated Transcriptomic and Proteomic Analysis Identifies Plasma Biomarkers of Hepatocellular Failure in Alcohol-Associated Hepatitis.

Josepmaria Argemi, Komal Kedia, Marina A Gritsenko, Ana Clemente-Sanchez, Aliya Asghar, Jose M Herranz, Zhang-Xu Liu, Stephen R Atkinson, Richard D Smith, Trina M Norden-Krichmar and 7 more

Open access · greenAbstract read
In one paragraph

Article in The American journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Alcohol-associated liver disease.The Journal of clinical investigation · 2024
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Josepmaria ArgemiDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania; Hepatology Program, Centro de Investigación Médica Aplicada, Liver Unit, Clinica Universidad de Navarra, Instituto de Investigacion de Navarra, Universidad de Navarra, Pamplona, Spain.
Komal KediaDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co, Inc., West Point, Pennsylvania.
Marina A GritsenkoBiological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington.
Ana Clemente-SanchezDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania; Biomedical Research Networking Center in Hepatic and Digestive Diseases, Instituto de Salud Carlos III, Madrid, Spain.
Aliya AsgharGasteroenterology Service, VA Long Beach Healthcare System, Long Beach, California.
Jose M HerranzHepatology Program, Centro de Investigación Médica Aplicada, Liver Unit, Clinica Universidad de Navarra, Instituto de Investigacion de Navarra, Universidad de Navarra, Pamplona, Spain.
Zhang-Xu LiuDivision of Gastrointestinal and Liver Disease, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Stephen R AtkinsonDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Richard D SmithBiological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington.
Trina M Norden-KrichmarDepartment of Epidemiology, School of Medicine, University of California, Irvine, Irvine, California.
Le Z DayBiological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington.
Andrew StolzDivision of Gastrointestinal and Liver Disease, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
John A TayekHarbor-University of California, Los Angeles Medical Center, Torrance, California.
Ramon BatallerDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Timothy R MorganGasteroenterology Service, VA Long Beach Healthcare System, Long Beach, California. Electronic address: timothy.morgan@va.gov.
Jon M JacobsBiological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington. Electronic address: jon.jacobs@pnnl.gov.
Southern California Alcoholic Hepatitis Consortium and the InTeam Consortium
Pacific Northwest National Laboratory · USUniversity of Pittsburgh · USUniversity of Southern California · USVA Long Beach Healthcare System · USClinica Universidad de Navarra · ESMerck & Co., Inc., Rahway, NJ, USA (United States) · USUCLA Medical Center · USUniversity of California, Irvine · US

Funding

Equipment Supplement Request for a Research Resource for Ultra-sensitive High Throughput ProteomicsP41GM103493 · NIGMS · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI SMITH, RICHARD D · 2012 to 2022
$22.6M
Molecular Subtypes for Targeted Therapies in Alcoholic HepatitisU01AA021908 · NIAAA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BATALLER, RAMON · 2013 to 2017
$6.0M
A prospective, randomized, clinical trial to evaluate two novel therapies, mycophU01AA021886 · NIAAA · SOUTHERN CALIFORNIA INST FOR RES/EDUC · PI MORGAN, TIMOTHY ROSS · 2013 to 2017
$3.1M
Immunity in alcoholic hepatitis.U01AA021857 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LIU, ZHANGXU · 2013 to 2017
$1.5M
Proteomic Investigations of Alcoholic HepatitisU01AA021918 · NIAAA · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI JACOBS, JON · 2013 to 2017
$1.3M
Transcriptomics of Liver in Alcoholic HepatitisU01AA021838 · NIAAA · UNIVERSITY OF CALIFORNIA-IRVINE · PI NORDEN-KRICHMAR, TRINA · 2013 to 2017
$1.3M
Liver-enriched Transcription Factors as Prognostic Markers and Therapeutic Targets in Alcoholic HepatitisU01AA026972 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ARTEEL, GAVIN E · 2018 to 2022
$1.2M
Spatial analysis of Alcoholic Hepatitis Liver TissueR21AA028117 · NIAAA · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI JACOBS, JON · 2020 to 2021
$445k
Southern California Alcoholic Hepatitis Consortium Administrative CoreU01AA021884 · NIAAA · SOUTHERN CALIFORNIA INST FOR RES/EDUC · PI MORGAN, TIMOTHY ROSS · 2013 to 2016
$118k
NIAAA NIH HHS R21 AA028117NIAAA NIH HHS U01 AA021838NIAAA NIH HHS U01 AA021857NIAAA NIH HHS U01 AA021884NIAAA NIH HHS U01 AA021886NIAAA NIH HHS U01 AA021908NIAAA NIH HHS U01 AA021918NIAAA NIH HHS U01 AA026972NIGMS NIH HHS P41 GM103493
6 · The paper itself

Abstract

Alcohol-associated hepatitis (AH) is a form of liver failure with high short-term mortality. Recent studies have shown that defective function of hepatocyte nuclear factor 4 alpha (HNF4a) and systemic inflammation are major disease drivers of AH. Plasma biomarkers of hepatocyte function could be useful for diagnostic and prognostic purposes. Herein, an integrative analysis of hepatic RNA sequencing and liquid chromatography-tandem mass spectrometry was performed to identify plasma protein signatures for patients with mild and severe AH. Alcohol-related liver disease cirrhosis, nonalcoholic fatty liver disease, and healthy subjects were used as comparator groups. Levels of identified proteins primarily involved in hepatocellular function were decreased in patients with AH, which included hepatokines, clotting factors, complement cascade components, and hepatocyte growth activators. A protein signature of AH disease severity was identified, including thrombin, hepatocyte growth factor α, clusterin, human serum factor H-related protein, and kallistatin, which exhibited large abundance shifts between severe and nonsevere AH. The combination of thrombin and hepatocyte growth factor α discriminated between severe and nonsevere AH with high sensitivity and specificity. These findings were correlated with the liver expression of genes encoding secreted proteins in a similar cohort, finding a highly consistent plasma protein signature reflecting HNF4A and HNF1A functions. This unbiased proteomic-transcriptome analysis identified plasma protein signatures and pathways associated with disease severity, reflecting HNF4A/1A activity useful for diagnostic assessment in AH.

Indexed as

Carcinoma, HepatocellularHepatitis, AlcoholicLiver NeoplasmsBiomarkersHepatocyte Growth FactorHumansProteinsProteomicsThrombinTranscriptomeBiomarkersHepatocyte Growth FactorProteinsThrombin

Identifiers

PMID36243044
PMCPMC9765311
OpenAlexW4304889612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.